Portal de investigación
Transcranial magnetic stimulation follow-up study in early Parkinson's disease: A decline in compensation with disease progression?
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Kojovic, M
- Kassavetis, P
- Bologna, M
- Parees, I
- Beraredelli, A
- Edwards, MJ
- Rothwell, JC
- Bhatia, KP
Abstract
BackgroundA number of neurophysiological abnormalities have been described in patients with Parkinson's disease, but very few longitudinal studies of how these change with disease progression have been reported. We describe measures of motor cortex inhibition and plasticity at 6 and 12 mo in 12 patients that we previously reported at initial diagnosis. Given the well-known interindividual variation in these measures, we were particularly concerned with the within-subject changes over time. MethodsPatients were assessed clinically, and transcranial magnetic stimulation (TMS) was used to measure motor cortical excitability, inhibition (short interval intracortical inhibition, cortical silent period), and plasticity (response to excitatory paired associative stimulation protocol) in both hemispheres. All measurements were performed 6 mo and 12 mo after the baseline experiments. ResultsAsymmetry in clinical motor symptoms was reflected in asymmetry of plasticity and inhibition. In the group as a whole, little change was seen in any of the parameters over 12 mo. However, analysis of within-individual data showed clear correlations between changes in clinical asymmetry and asymmetry of response to paired associative stimulation protocol and cortical silent period. ConclusionsLongitudinal changes in cortical silent period and response to paired associative stimulation protocol in Parkinson's disease reflect dynamic effects on motor cortex that are related to progression of motor signs. They are useful objective markers of early disease progression that could be used to detect effects of disease-modifying therapies. The decline in heightened plasticity that was present at disease onset may reflect failure of compensatory mechanisms that maintained function in the preclinical state. (c) 2015 International Parkinson and Movement Disorder Society
Datos de la publicación
- ISSN/ISSNe:
- 0885-3185, 1531-8257
- Tipo:
- Article
- Páginas:
- 1098-1106
- DOI:
- 10.1002/mds.26167
- Factor de Impacto:
- 2,838 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
MOVEMENT DISORDERS WILEY
Citas Recibidas en Web of Science: 48
Documentos
- No hay documentos
Filiaciones
Keywords
- Parkinson's disease; progression; transcranial magnetic stimulation; PAS; sensorimotor cortical plasticity
Campos de estudio
Proyectos asociados
ESTUDIO PROSPECTIVO, FASE IIB/III, MULTICÉNTRICO, RANDOMIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, DE GRUPOS PARALELOS PARA COMPARAR LA EFICACIA Y SEGURIDAD DE MASITINIB FRENTE A PLACEBO EN EL TRATAMIENTO DE PACIENTES CON PARÁLISIS SUPRANUCLEAR PROGRESIVA (PSP).
Investigador Principal: IRENE MARTÍNEZ TORRES
AB13004 . 2016
ESTUDIO PROSPECTIVO, OBSERVACIONAL PARA EVALUAR LOS PATRONES DE DISTONÍA CERVICAL ANTES Y DESPUÉS DE UN CICLO DE TRATAMIENTO CON TOXINA BOTULINICA TIPO A (BONT-A).
Investigador Principal: JUAN ANDRES BURGUERA HERNANDEZ
IPS-TOX-2012-03
EFICACIA Y SEGURIDAD DE LA TROMBÓLISIS ENDOVENOSA BASADA EN CRITERIOS RESONANCIA MAGNÉTICA EN EL ICTUS DEL DESPERTAR: ENSAYO CLÍNICO, ALEATORIZADO, DOBLE CIEGO CONTROLADO CON PLACEBO.
Investigador Principal: JOSÉ IGNACIO TEMBL FERRAIRO
WAKE-UP . 2014
ESTUDIO EN FASE III, ALEATORIZADO, CON DOBLE ENMASCARAMIENTO Y CONTROLADO CON PLACEBO SOBRE LA LISIS DE TROMBOS COMBINADA CON ULTRASONIDOS Y EL ACTIVADOR TISULAR DEL PLASMINÓGENO (TPA) SISTÉMICO PARA LA REVASCULARIZACIÓN EMERGENTE (CLOTBUST-ER) EN EL ICTU S ISQUÉMICO AGUDO. (CLOTBUSTER COMBINED LYSIS OF THROMBUS WITH ULTRASOUND AND SYSTEMIC TISSUE PLASMINOGEN ACTIVATOR (TPA) FOR EMERGENT REVASCULARIZATION).
Investigador Principal: JOSÉ IGNACIO TEMBL FERRAIRO
CP-01
Cita
Kojovic M,Kassavetis P,Bologna M,Parees I,Rubio I,Beraredelli A,Edwards MJ,Rothwell JC,Bhatia KP. Transcranial magnetic stimulation follow-up study in early Parkinson's disease: A decline in compensation with disease progression?. Mov Disord. 2015. 30. (8):p. 1098-1106. IF:6,010. (1).